Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

The series C round consisted of $77m in equity funding and $25m in venture debt, with Kaiser Permanente among the participants.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

Kaiser Permanente Ventures and Samsung Next invested in the digital mental health treatment developer through a series B round that will fund product development and commercialisation.

Engrail Therapeutics has completed a series A round led by Nan Fung Life Sciences as it targets a validated mechanism-based approach to nervous system treatments.

Axa Venture Partners was among the limited partners that have helped the deep tech-focused venture firm raise $59.4m for its second fund.

Optum Ventures co-led a series B round that took the chronic disease management platform's total funding to $50m.

The pharmaceutical firm has transferred China-based business development director Manabu Aruga to its Tokyo headquarters where he will oversee corporate VC deals in Asia.

The universities of Edinburgh, Manchester, Glasgow and Aberdeen have all contributed to Epidarex’s latest fund, which will invest in life sciences spinouts.

Kaiser Permanente contributed to a round that pushed the total raised by the Stanford-aligned cellular cancer therapy developer to $300m.